Form 4: Revance Therapeutics Director Angus C. Russell Disposes of Shares Following Merger Agreement

Director Angus C. Russell reports the disposal of Revance Therapeutics shares following the completion of a merger with Crown Laboratories, Inc.

Summary

• Angus C. Russell, a director of Revance Therapeutics, reported changes in beneficial ownership of the company's stock on February 6, 2025.
• The report details the disposal of 36,506 shares of common stock at a price of $3.65 per share.
• These shares were tendered for purchase pursuant to a cash tender offer by Crown Laboratories, Inc. as part of a merger agreement.
• Additionally, 15,000 restricted stock awards held by Russell were canceled and converted into the right to receive $3.65 per share, as per the merger agreement.
• Following these transactions, Russell's direct ownership of Revance Therapeutics common stock is reported as zero.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports on a completed transaction (merger). There are no explicit positive or negative implications for the company's future performance mentioned in the filing.

Future Outlook

The document does not contain any specific forward-looking statements regarding the future outlook of the company, as it primarily reports on the completion of the merger.

Industry Context

This announcement reflects a merger and acquisition activity within the biotechnology or pharmaceutical industry, where companies are often acquired to consolidate resources, technologies, or market share. Crown Laboratories' acquisition of Revance Therapeutics suggests a strategic move to expand its portfolio or capabilities in a related area.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, with deal sizes varying greatly depending on the target company's assets and potential.
• Comparable deals might include acquisitions of companies with promising drug candidates or established market presence in specific therapeutic areas.
• The $3.65 per share price reflects the valuation agreed upon during the merger negotiations, which may be influenced by factors such as market conditions, financial performance, and future growth prospects.

Stakeholder Impact

• Shareholders received $3.65 per share as part of the merger agreement.
• Employees' job security and roles may be affected by the merger, depending on the integration plans of Crown Laboratories.
• The merger could lead to changes in the availability or pricing of Revance Therapeutics' products for customers.

Key Dates

Keywords

Revance Therapeutics, Angus C. Russell, Crown Laboratories, Merger Agreement, Form 4, Beneficial Ownership, Share Disposal, Cash Tender Offer, Director, RVNC